You are here:Home-Chemical Inhibitors & Agonists-Tyrosine Kinase-EGFR-Dacomitinib
Dacomitinib

Chemical Structure : Dacomitinib

CAS No.: 1110813-31-4

Dacomitinib (PF-00299804;PF-299804;PF 299804;PF 00299804)

Catalog No.: PC-43452Not For Human Use, Lab Use Only.

Dacomitinib (PF-00299804, PF-299804) is a potent, irreversible, orally active pan-ErbB receptor tyrosine kinase inhibitor with IC50 of 6, 45.7 and 73.7 for EGFR, ERBB2 and ERBB4, respectively.

Packing Price Stock Quantity
25 mg $128 In stock
50 mg $188 In stock
100 mg $288 In stock
200 mg Get quote
1 g Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

Dacomitinib (PF-00299804, PF-299804) is a potent, irreversible, orally active pan-ErbB receptor tyrosine kinase inhibitor with IC50 of 6, 45.7 and 73.7 for EGFR, ERBB2 and ERBB4, respectively.
Dacomitinib (PF-00299804, PF-299804) irreversibly inhibits erbB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of erbB family members inhibits erbB1 autophosphorylation in the A431 human squamous cell carcinoma line with IC50 of 15.1 nM.
Dacomitinib (PF-00299804, PF-299804) causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in EGFR associated with resistance to gefitinib and erlotinib.

Physicochemical Properties

M.Wt 469.94
Formula C24H25ClFN5O2
Appearance Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility

DMSO: ≥ 50 mg/mL (Need ultrasonic)

Chemical Name/SMILES

2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-

References

1. Engelman JA, et al. Cancer Res. 2007 Dec 15;67(24):11924-32.

2. Gonzales AJ, et al. Mol Cancer Ther. 2008 Jul;7(7):1880-9.

3. Nguyen KS, et al. Clin Lung Cancer. 2009 Jul;10(4):281-9.

4. Kalous O, et al. Mol Cancer Ther. 2012 Sep;11(9):1978-87.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: